New vaccine created by the Duke Vaccine Institute, in preclinical tests proved its effectiveness against various coronavirus infections, including SARS-COV-1, SARS-COV-2 and related pathogens of bats that can cause the following pandemic. This is reported in an article published in the journal Nature.
The pankonavorus vaccine activates antibodies due to nanoparticles, which consist of a fragment of the coronavirus (plays the role of immunogen) and adjuvant – compounds that enhances the immune response in response to the introduction into the organism of immunogen. Antibodies induced by vaccine in Makakov and mice successfully neutralized not only the classic strain of Wuhan Coronavirus, but also new options arising in the UK, South Africa and Brazil.
In previous studies, scientists have identified one particular receptor-binding domain website, which is present at SARS-COV-2, has its circulating options, as well as the coronaviruses of bats associated with SARS. The presence of this domain characteristic of all pathogenic and potentially dangerous coronaviruses makes all these pathogens are very vulnerable to cross-neutralizing antibodies. The command then developed a nanoparticle with an adjuvant 3M-052 – agonist of tall-like receptors 7 and 8, which recognize the structural characteristic of pathogens and activate the immune response.
During tests on monkeys, the new vaccine blocked COVID-19 infection by 100 percent. Nanoparticles also caused significantly higher levels of neutralization in animals than existing vaccines or natural infection in humans.
Over the past 20 years, betacovs (Betacovs) caused outbreaks of heavy acute respiratory syndrome (SARS), Middle Eastern respiratory syndrome (MERS), as well as SARS-COV-2 pandemic. There is a high probability that they will also cause a new pandemic in the future.